<DOC>
<DOCNO>EP-1040099</DOCNO> 
<TEXT>
<INVENTION-TITLE>
AZEPINE OR LARGER MEDIUM RING DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31395	A61K31395	A61K3155	A61K3155	A61P100	A61P100	A61P104	A61P300	A61P310	A61P900	A61P900	A61P910	A61P1100	A61P1100	A61P1106	A61P1300	A61P1312	A61P1700	A61P1700	A61P1706	A61P1900	A61P1902	A61P1908	A61P2500	A61P2528	A61P2700	A61P2702	A61P2900	A61P2900	A61P3100	A61P3112	A61P3118	A61P3122	A61P3500	A61P3500	A61P3504	A61P3700	A61P3704	A61P4300	A61P4300	C07D22300	C07D22306	C07D22308	C07D22312	C07D22500	C07D22502	C07D40100	C07D40104	C07D40112	C07D40500	C07D40504	C07D40900	C07D40904	C07D40912	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P1	A61P1	A61P1	A61P3	A61P3	A61P9	A61P9	A61P9	A61P11	A61P11	A61P11	A61P13	A61P13	A61P17	A61P17	A61P17	A61P19	A61P19	A61P19	A61P25	A61P25	A61P27	A61P27	A61P29	A61P29	A61P31	A61P31	A61P31	A61P31	A61P35	A61P35	A61P35	A61P37	A61P37	A61P43	A61P43	C07D223	C07D223	C07D223	C07D223	C07D225	C07D225	C07D401	C07D401	C07D401	C07D405	C07D405	C07D409	C07D409	C07D409	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Selected novel azepine and larger medium ring compounds are effective for prophylaxis and treatment of inflammation, tissue degradation and related diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of inflammation, tissue degradation and related diseases. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
AMGEN INC
</APPLICANT-NAME>
<APPLICANT-NAME>
AMGEN INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HUMMEL CONRAD
</INVENTOR-NAME>
<INVENTOR-NAME>
KOCH KEVIN
</INVENTOR-NAME>
<INVENTOR-NAME>
RUSSO-RODRIGUEZ SANDRA E
</INVENTOR-NAME>
<INVENTOR-NAME>
TERMIN ANDREAS
</INVENTOR-NAME>
<INVENTOR-NAME>
HUMMEL, CONRAD
</INVENTOR-NAME>
<INVENTOR-NAME>
KOCH, KEVIN
</INVENTOR-NAME>
<INVENTOR-NAME>
RUSSO-RODRIGUEZ, SANDRA, E.
</INVENTOR-NAME>
<INVENTOR-NAME>
TERMIN, ANDREAS
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 AZEPINE OR LARGER MEDIUM RING DERIVATIVES AND THEIR USE AS PHARMACEUTICALSBACKGROUND OF THE INVENTION The present invention relates to metalloproteinase inhibitors and, more particularly, relates to novel compounds, compositions and methods for prophylaxis and treatment of inflammation, tissue degradation and the like. This invention, in particular, relates to novel azepine and larger medium ring compounds, compositions containing such compounds and methods of use of such compounds. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. Metalloproteinase enzymes, such as collagenases , stromelysins, gelatinases and TNF convertase, may contribute to the onset or etiology of, or exacerbate disease states which are related to, connective tissue degradation, secretion of proinflammatory cytokines and the like. For example, matrix metalloproteinases, such as collagenases, stromelysins and gelatinases, are thought to be involved in the tissue breakdown observed in rheumatoid arthritis; osteoarthritis; osteopenias (e.g., osteoporosis); periodontitis; gingivitis; corneal, epidermal and gastric ulceration; and tumour metastasis, invasion and growth; in neuroinflammatory disorders, such as myelin degradation (e.g., multiple sclerosis); and in angiogenesis dependent diseases, such as arthritic conditions; cancer; solid tumor growth; psoriasis; proliferative retinopathies; neovascular glaucoma; ocular tumours; angiofibromas ; hemangiomas ; nephritis; pulmonary inflammation; and restenosis.Tumor Necrosis Factor alpha (TNF-α) is a proinflammatory cytokine secreted by a variety of cells including monocytes and macrophages in response to many inflammatory stimuli (e.g., lipopolysaccharide - LPS) or external cellular stress (e.g., osmotic shock, 

peroxide) . Elevated levels of TNF play a major role in mediating many inflammatory disease states . Elevated levels of TNF-α may contribute to the onset, etiology, or exacerbate the following disease states: rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; antiviral therapy including those viruses sensitive to TNF-α inhibition - HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, and the herpes viruses including HSV-1, HSV- 2, and herpes zoster; muscle degeneration; cachexia;
</DESCRIPTION>
<CLAIMS>
WHAT IS CLAIMED IS:
1. A compound of formula

 or a pharmacutically acceptable salt thereof, wherein
1
R is (1) an alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl radical optionally substituted by 1-3 radicals of -OH, -OR
3
, -SR
3
, -S(0)R
3
, 


 -C(0)R
3
,
3
 4 -NR R , aryl, heteroaryl, cycloalkyl or heterocyclyl; or
(2) an aryl radical optionally substituted by an optionally substituted monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; or (3) a heteroaryl radical optionally substituted by an optionally substituted phenyl or a monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; wherein the phenyl, aryl, heteroaryl, cycloalkyl and heterocyclyl radicals of (1), (2) and (3) are optionally substituted
3 3 3 by 1-3 radicals of hydroxy, -OR , -SR , -S(0)R ,
3 3 3 4 ,
-S(0)
2
R , -C(0)R , -NR R , ammo, alkanoylamino, alkylsulfonylamino, alkoxycarbonylamino, alkoxycarbonyl, cyano, halo, azido, alkyl or haloalkyl; provided that the total number of phenyl, aryl, heteroaryl, cycloalkyl
1 and heterocyclyl radicals in R is 0-3;
wherein each R is independently an alkyl, haloalkyl, aryl, heteroaryl, aryl-alkyl or heteroaryl-alkyl 


radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylamino, alkoxycarbonyl, cyano, halo, azido,
4 alkyl, haloalkyl or haloalkoxy; and each R is independently a hydrogen or alkyl radical;
2
R is a hydrogen or alkyl radical;
8 11 8 11 12 , 11 12
V is -CR R - or -CR R -CHR - ; wherein R and R are
20 21 22 each independently (1) a hydrogen, -OR , -SR , -C(0)R ,
33 31 33 30 33 32 31 33
-NR -C(0)-R , -NR -C(0)-OR , -NR -C(0)-NR R , -NR -
30 33 32 31 , ,
S(0)
2
-R / -NR -S(0) -NR R , cycloalkyl, aryl or heteroaryl radical; or (2) an alkyl, alkenyl or alkynyl radical optionally substituted with 1-3 radicals of -
20 21 22 33 31 33 30
OR , -SR , -C(0)R , -NR -C(0)-R , -NR -C(0)-OR , -
33 32 31 33 30 33 , 32 31
NR -C(0)-NR R , -NR -S(0)
2
-R , -NR -S(0)
2
-NR R , aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkanoylamino, alkylsulfonylamino, alkoxycarbonylamino, alkoxycarbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy;
20 wherein each R is independently a hydrogen, alkyl, alkenyl, aryl, heteroaryl, aryl-alkyl, heteroaryl-alkyl , alkanoyl, aroyl or heteroaroyl radical; wherein the alkyl and alkenyl radicals are optionally substituted by
22 -C(0)R ; and wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, 


alkoxycarbonylamino, alkoxycarbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy; and
21 . 22 each R is independently an alkyl, alkyl-C(0)R , aryl, heteroaryl, aryl-alkyl or heteroaryl-alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylamino, alkoxycarbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy;
22 wherein each R is independently a hydroxy, alkoxy, aryloxy, aryl-alkoxy, heteroaryloxy, heteroaryl-alkoxy
23 24 , . 23 . or -NR R radical; wherein each R is independently a hydrogen, alkyl, aryl, aryl-alkyl, heteroaryl or
24 heteroaryl-alkyl radical; and each R is independently
23 24 a hydrogen or alkyl radical; or -NR R represents a heterocyclyl or heteroaryl radical ; wherein the
22 23 heterocyclyl, aryl and heteroaryl radicals of R , R
23 24 and -NR R are optionally substituted by 1-3 radicals of hydroxy, alkoxy, alkylthiol, amino, alkanoylamino, alkylsulfonylamino, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylamino, alkoxycarbonyl, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy; and
5 6 7 8
R , R , R and R are each independently a hydrogen or
5 6 6 7 7 8 . alkyl radical; or one of CR -CR , CR -CR or CR -CR is
C=C;
9 10 wherein R and R are each independently -B-A, provided that the combined total number of aryl, heteroaryl, 


 9 10 11 cycloalkyl and heterocyclyl radicals in R , R , R and
12 .
R is 0-3;
wherein each B is independently a (1) bond;
(2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano or halo, and/or (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl, haloalkyl or haloalkoxy;
(3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl, haloalkyl or haloalkoxy; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl, haloalkyl or haloalkoxy;
each A is independently a
(1) hydrogen radical;
(2) halo, cyano or nitro radical;
3 300 3 111 32 31 , 32 32 31 ( (33)) - -CC((0O))-- -RR ,, - -CC((00))--OORR
"
 , -C(0)~NR R or -C (NR ) -NR R radical ;
31
( 4 ) -OR , -0- -C (0 ) -R
31
 , - -0-C(0)-NR
32
R
31
 or -0-C(0)-NR -
S(0)
2
-R radical; 


 31 30 , 30 32 31
(5) -SR , -S(0)-R , -S(0)
2
-R , -S(0)
2
-NR R , -S(0)
2
- NR
33
-C(0)-R
31
, -S(0)
2
-NR
33
-C(0)-OR
3
° or -S (0) 
2
-NR
33
-C (0) -
32 31
NR R radical; or
32 31 33 , 31 33 30 33 , .
(6) -NR R , -NR -C(0)-R , -NR -C(0)-OR , -NR -C(O)-
32 31 33 32 32 31 33 30 33 NR R , -NR -C(NR ) -NR R , -NR -S(0)
2
-R or -NR -
32 31
S(0)
2
-NR R radical;
30 wherein each R is independently
(1) alkyl, alkenyl or alkynyl radical optionally
34 substituted by 1-3 radicals of -C0R , ammo, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino , N- (alkoxycarbonyl ) -N- (alkyl ) amino , ammocarbonylamino , alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo or aralkoxy, arylalkylthio, arylalkylsulfonyl, cycloalkyl, heterocyclyl, aryl or heteroaryl radicals, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkanoyl, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl, haloalkyl or haloalkoxy;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, alkyl, haloalkyl or haloalkoxy; or
(3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl, haloalkyl or haloalkoxy; 


 31 30 each R is independently hydrogen radical or R ;
32 wherein each R is independently
(1) hydrogen radical; (2) alkyl, alkenyl or alkynyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano or halo; or
(3) aryl, heteroaryl, arylalkyl, heteroarylalkyl , heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl, haloalkyl or haloalkoxy; and
33 each R is independently
(1) hydrogen radical;
(2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl which is optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl, haloalkyl or haloalkoxy; or (3) heterocyclyl, aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl, haloalkyl or haloalkoxy; and
34 each R is independently hydrogen, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, 


alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl, haloalkyl or haloalkoxy.
2. The compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein
R is (1) an C
1
-C
12
 alkyl, C
2
-Cι alkenyl, C
2
-Cι
2
 alkynyl, cycloalkyl or heterocyclyl radical optionally 3 3 substituted by 1-3 radicals of -OH, -OR , -SR , -S(0)R ,
3 3 3 4 -S(0)
2
R , -C(0)R , -NR R , aryl, heteroaryl, cycloalkyl or heterocyclyl; or (2) an aryl radical optionally substituted by an optionally substituted monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; or (3) a heteroaryl radical optionally substituted by an optionally substituted phenyl or a monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; wherein the phenyl , aryl , heteroaryl , cycloalkyl and heterocyclyl radicals of (1), (2) and (3) are optionally substituted by 1-3 radicals of hydroxy, -OR
3
, -SR
3
, -S(0)R
3
,
3 3 3 4 -S(0)
2
R , -C(0)R , -NR R , ammo, Ci-Cs alkanoylamino, Cι~
C
8
 alkylsulfonylamino, Ci-Cs alkoxycarbonylamino, Ci-Cs alkoxycarbonyl, cyano, halo, azido, Ci-Cβ alkyl or Ci-Cs haloalkyl of 1-3 halo radicals; provided that the total number of phenyl, aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R is 0-3;
wherein each R is independently a Ci-Cs alkyl, Ci-Cs haloalkyl of 1-3 halo radicals, aryl, heteroaryl, aryl- 



Cι-C
4
-alkyl or heteroaryl-Cι-C
4
~alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C
1
-C
4
 alkoxy, C
1
-C
4
 alkylthiol, amino, Ci-Cs alkanoylamino, Ci-Cs alkylsulfonylamino, C
1
-C
4
 alkylsulfinyl, C
1
-C
4
 alkylsulfonyl, Ci-Cs alkoxycarbonylamino, Ci-Cs alkoxycarbonyl, cyano, halo, azido, Ci-Cg alkyl, Ci-Cβ haloalkyl of 1-3 halo radicals or Ci-Cs haloalkoxy of 1-
4 3 halo radicals ; and each R is independently a hydrogen or Ci-Cβ alkyl radical;
2 R is a hydrogen or C
1
-C
4
 alkyl radical;
8 11 8 11 12 . 11 12 V is -CR R - or -CR R -CHR - ; wherein R and R are
20 21 22 each independently (1) a hydrogen, -OR , -SR , -C(0)R ,
33 31 33 30 33 32 31 33
-NR -C(0)-R , -NR -C(0)-OR , -NR -C(0)-NR R , -NR - S(0)
2
-R , -NR -S(0)
2
-NR R , cycloalkyl, aryl or heteroaryl radical; or (2) an Cχ-C
8
 alkyl, C
2
-Cs alkenyl or C -C
8
 alkynyl radical optionally substituted with 1-3
20 21 22 33 31 33 radicals of -OR , -SR , -C(0)R , -NR -C(0)-R , -NR -
30 33 32 31 33 30 33 , 
%
C(0)-OR , -NR -C(0)-NR R , -NR -S(0)
2
-R , -NR -S(0)
2
-
32 31
NR R , aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-3 radicals of hydroxy, C
1
-C
4
 alkoxy, C
1
-C
4
 alkylthiol, amino, Ci-Cs alkanoylamino, Ci-Cs alkylsulfonylamino, C
1
-C
4
 alkylsulfinyl, C
1
-C
4
 alkylsulfonyl, Cχ-C
8
 alkoxycarbonylamino, Ci-Cs alkoxycarbonyl, cyano, halo, azido, Ci-Cs alkyl, Ci-Cs haloalkyl of 1-3 halo radicals or Ci-Cβ haloalkoxy of 1- 3 halo radicals; 


 20 , wherein each R is independently a hydrogen, Ci-Cβ alkyl, C
2
-Cβ alkenyl, aryl, heteroaryl, aryl-Cι-C
4
- alkyl, heteroaryl-Cι-C
4
-alkyl, Ci-Cs alkanoyl, aroyl or heteroaroyl radical; wherein the alkyl and alkenyl
22 radicals are optionally substituted by -C(0)R ; and wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C
1
-C
4
 alkoxy, C
1
-C
4
 alkylthiol, amino, Ci-Cβ alkanoylamino, Ci-Cs alkylsulfonylamino, C
1
-C
4
 alkylsulfinyl, C
1
-C
4
 alkylsulfonyl, Ci-Cβ alkoxycarbonylamino, Ci-Cs alkoxycarbonyl, cyano, halo, azido, Ci-Cs alkyl, Ci-Cs haloalkyl of 1-3 halo radicals or Ci-Cs haloalkoxy of 1- 3 halo radicals; and
21 each R is independently a Ci-Cβ alkyl, Ci-Cβ
22 alkyl-C(0)R , aryl, heteroaryl, aryl-Cι-C
4
~alkyl or heteroaryl-Cι~C
4
-alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C
1
-C
4
 alkoxy, C
1
-C
4
 alkylthiol, amino, Ci-Cβ alkanoylamino, Ci-Cβ alkylsulfonylamino, Ci- C
4
 alkylsulfinyl, C
1
-C
4
 alkylsulfonyl, Ci-Cs alkoxycarbonylamino, Ci-Cs alkoxycarbonyl, cyano, halo, azido, Ci-Cs alkyl, Ci-Cβ haloalkyl of 1-3 halo radicals or Ci-Cs haloalkoxy of 1-3 halo radicals;
22 wherein each R is independently a hydroxy, Ci-Cβ alkoxy, aryloxy, aryl-C_-C
4
-alkoxy, heteroaryloxy,
23 24 heteroaryl-Cι-C
4
~alkoxy or -NR R radical; wherein each
23
R is independently a hydrogen, Ci-Cs alkyl, aryl, aryl- Cι-C
4
-alkyl, heteroaryl or heteroaryl-Cι-C
4
-alkyl
24 radical; and each R is independently a hydrogen or Ci-
23 24
Cβ alkyl radical; or -NR R represents a heterocyclyl 


or heteroaryl radical; wherein the heterocyclyl, aryl
-, . -, 22 23 , 23 24 and heteroaryl radicals of R , R and -NR R are optionally substituted by 1-3 radicals of hydroxy, C
1
-C
4
 alkoxy, C
1
-C
4
 alkylthiol, amino, Ci-Cs alkanoylamino, Cχ~ Cζ alkylsulfonylamino, C
1
-C
4
 alkylsulfinyl, C
1
-C
4
 alkylsulfonyl, Cχ-Cs alkoxycarbonylamino, Cχ-Cs alkoxycarbonyl, cyano, halo, azido, Cχ-Cs alkyl, Cχ-Cs haloalkyl of 1-3 halo radicals or Cχ-Cβ haloalkoxy of 1- 3 halo radicals; and
5 6 7 8
R , R , R and R are each independently a hydrogen or
5 6 6 7 7 8
Cχ-C
4
 alkyl radical; or one of CR -CR , CR -CR or CR -CR is C=C;
9 10 wherein R and R are each independently -B-A, provided that the combined total number of aryl, heteroaryl,
9 10 11 cycloalkyl and heterocyclyl radicals m R , R , R and 

wherein each B is independently a
(1) bond;
(2) C -C
δ
 alkyl, C
2
-Cs alkenyl or C
2
-C
8
 alkynyl radical optionally substituted by (a) 1-3 radicals of amino, Cχ~ C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, hydroxy, Cχ-C
4
 alkoxy, C -C
4
 alkylthio, cyano or halo, and/or (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, hydroxy, Cχ-C
4
 alkoxy, Cχ-C alkylthio, cyano, halo, C -C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1-3 halo radicals; 


(3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C -C
4
 alkylamino, di-(Cχ-C
4
 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthio, cyano, Cχ-C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or Cχ-C
4
 haloalkoxy of 1- 3 halo radicals; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di- (Cχ-C
4
 alkyDamino, C -C
5
 alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, hydroxy, Cχ-C
4
 alkoxy, Cχ-C
4
 alkylthio, cyano, halo, C -C
4
 alkyl, Cχ-C
δ
 haloalkyl of 1-3 halo radicals or Cχ-Cs haloalkoxy of 1-3 halo radicals;
each A is independently a
(1) hydrogen radical;
(2) halo, cyano or nitro radical;
30 31 32 31 , 32
^
 32 31
(3) -C(0)-R , -C(0)-OR , -C(0)-NR R or -C (NR ) -NR R radical;
(4) -OR
31
, -0-C(0)-R
31
, -0-C(0)-NR
32
R
31
 or -0-C(0)-NR -
30
S(0)
2
-R radical;
31 30 30 32 31 , .
(5) -SR , -S(0)-R , -S(0)
2
-R , -S(0)
2
-NR R , -S(0)
2
- NR
33
-C(0)-R
31
, -S(0)
2
-NR
33
-C(0)-OR
3
° or -S(0)
2
"NR -C(O)-
32 31 NR R radical; or
32 31 33 31 33 30 33 , ,
(6) -NR R , -NR -C(0)-R , -NR -C(0)-OR , -NR -C(O)-
32 31 33 32 32 31 33 30 33
NR R , -NR -C(NR ) -NR R , -NR -S(0)
2
-R or -NR - S(0)
2
-NR R radical;
30 wherein each R is independently
(1) Cχ-C
8
 alkyl, C
2
-C
8
 alkenyl or C
2
-C
8
 alkynyl radical optionally substituted by 1-3 radicals of -CO
2
R , ammo, 


C -C
4
 alkylamino, di- (C -C
4
 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, N- ( (Cχ-C
4
 alkoxy) carbonyl) -N- (Cχ-C
4
 alkyDamino, aminocarbonylamino, C -C
4
 alkylsulfonylamino, hydroxy, Cχ-C
4
 alkoxy, C -C
4
 alkylthio, Cχ-C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, cyano, halo, aryl-Cχ-C
4
-alkoxy, aryl-Cχ- C
4
-alkylthio, aryl-Cχ-C
4
-alkylsulfonyl, C
3
-C
8
 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of amino, Cχ~ C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, Cχ-Cs alkanoyl, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, Cχ-C
4
 alkoxy, C -C
4
 alkylthio, C -C
4
 alkylsulfinyl, C -C
4
 alkylsulfonyl, cyano, halo,
Cχ-C
4
 alkyl, Cχ-C
4
 haloalkyl of 1-3 halo radicals or Cχ~ C
4
 haloalkoxy of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl, hydroxy, Cχ-C
4
 alkoxy, C
1
-C
4
 alkylthio, cyano, C -C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or Cχ-C
4
 haloalkoxy of 1-3 halo radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, C -C
5
 alkanoylamino, (C
1
-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, (C
1
-C4 alkoxy) carbonyl, hydroxy, Cχ-C
4
 alkoxy, C -C
4
 alkylthio, cyano, halo, azido, C -C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C
1
-C
4
 haloalkoxy of 1-3 halo radicals;
31 , 30 each R is independently hydrogen radical or R ; 

32 . wherein each R is independently
(1) hydrogen radical;
(2) Cχ-Cδ alkyl, C
2
-Cs alkenyl or C
2
-C
8
 alkynyl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di- (Cχ-C
4
-alkyl) amino, hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthio, cyano or halo; or
(3) aryl, heteroaryl, aryl-Cχ-C
4
-alkyl, heteroaryl-Cχ- C
4
-alkyl, heterocyclyl, heterocyclyl-Cχ-C
4
-alkyl, C
3
-C
8
 cycloalkyl or C
3
-C
8
-cycloalkyl-Cχ-C
4
-alkyl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di- (Cχ-C
4
-alkyl) amino, hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthio, cyano, C -C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C
1
-C
4
 haloalkoxy of 1- 3 halo radicals; and
33 each R is independently
(1) hydrogen radical;
(2) C -C
4
 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl which is optionally substituted by 1-3 radicals of amino, C -C4 alkylamino, di- (C -C
4
 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthio, Cχ-C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, cyano, halo, Cχ-C4 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1-3 halo radicals; or
(3) heterocyclyl, aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C -C
4
 alkylamino, di-(Cχ-C
4
 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, hydroxy, C
1
-C
4
 alkoxy, C -C
4
 alkylthio, Cχ-C
4
 alkylsulfinyl, C -C4 alkylsulfonyl, cyano, halo, Cχ-C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1-3 halo radicals; and 


 34 , each R is independently hydrogen or C -C
4
 alkyl, aryl, heteroaryl, aryl-Cχ-C
4
-alkyl or heteroaryl-Cχ-C
4
-alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of amino, C -C
4
 alkylamino, di-(Cχ-C
4
 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthio, C
1
-C
4
 alkylsulfinyl, C -C
4
 alkylsulfonyl, cyano, halo, C -C
4
 alkyl, Cχ-C
4
 haloalkyl of 1-3 halo radicals or Cχ-C
4
 haloalkoxy of 1-3 halo radicals; and
wherein cycloalkyl is a monocyclic, bicyclic or tricyclic carbocyclic alkyl radical of 3-10 ring members, which is optionally partially unsaturated or benzo-fused; heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5- 8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C
3
-C
4
~carbocyclic-fused.
3. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein
R is (1) a Cχ-C
12
 alkyl, C
2
-C
12
 alkenyl, C
2
-Cχ
2
 alkynyl, cycloalkyl or heterocyclyl radical optionally substituted by 1-3 radicals of -OH, -OR , -SR , -S(0)R , 


 3 3 3 4
-S(0)
2
 , -C(0)R , -NR R , aryl, heteroaryl, cycloalkyl or heterocyclyl; or (2) an aryl radical optionally substituted by an optionally substituted monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; or (3) a heteroaryl radical optionally substituted by an optionally substituted phenyl or a monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; wherein the phenyl, aryl, heteroaryl, cycloalkyl and heterocyclyl radicals of (1), (2) and (3) are optionally substituted
3 3 3 by 1-3 radicals of hydroxy, -OR , -SR , -S(0)R ,
3 3 3 4 . -S(0)
2
 , -C(0)R , -NR R , ammo, Cχ-C
4
 alkanoylamino, Cχ~ C
4
 alkylsulfonylamino, C -C
4
 alkoxycarbonylamino, C -C
4
 alkoxycarbonyl, cyano, halo, azido, Cχ-C
6
 alkyl or Cχ-C4 haloalkyl of 1-3 halo radicals; provided that the total number of phenyl, aryl, heteroaryl, cycloalkyl and
1 heterocyclyl radicals m R is 0-3;
wherein each R is independently a C -C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals, aryl, heteroaryl, aryl- Cχ-C
4
-alkyl or heteroaryl-Cχ-C
4
-alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthiol, amino, C -C
4
 alkanoylamino, C -C
4
 alkylsulfonylamino, Cχ-C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, C -C
4
 alkoxycarbonylamino, C -C
4
 alkoxycarbonyl, cyano, halo, azido, Cχ-C
4
 alkyl, Cχ-C4 haloalkyl of 1-3 halo radicals or Cχ-C
4
 haloalkoxy of 1-
4 3 halo radicals; and each R is independently a hydrogen or C -C
4
 alkyl radical; 


 8 11 8 11 12 , 11 12
V is -CR R - or -CR R -CHR -; wherein R and R are
20 21 22 each independently (1) a hydrogen, -OR , -SR , -C(0)R ,
33 31 33 30 33 32 31 33
-NR -C(0)-R , -NR -C(0)-0R , -NR -C(0)-NR R , -NR -
30 33 32 31
S(0)
2
-R , -NR -S(0)
2
-NR R , cycloalkyl, aryl or heteroaryl radical; or (2) an Cχ-Cs alkyl, C
2
-Cs alkenyl or C
2
-C
8
 alkynyl radical optionally substituted with 1-3 radicals of -OR
2
°, -SR
21
, -C(0)R
22
, -NR
33
-C (0)


 -NR -
30 33 32 31 33 30 33 , ,
C(0)-OR , -NR -C(0)-NR R , -NR -S(0)
2
-R , -NR -S(0)
2
-
32 31
NR R , aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, C -C
4
 alkanoylamino, C -C
4
 alkylsulfonylamino, C -C
4
 alkylsulfinyl, C -C
4
 alkylsulfonyl, Cχ-C
4
 alkoxycarbonylamino, C -C
4
 alkoxycarbonyl, cyano, halo, azido, Cχ-C
4
 alkyl, C -C4 haloalkyl of 1-3 halo radicals or Cχ-C
4
 haloalkoxy of 1- 3 halo radicals;
20 wherein each R is independently a hydrogen, C -C
4
 alkyl, C
2
-C
4
 alkenyl, aryl, heteroaryl, aryl-Cχ-C
4
- alkyl, heteroaryl-Cχ-C
4
-alkyl, C -C
4
 alkanoyl, aroyl or heteroaroyl radical; wherein the alkyl and alkenyl
22 radicals are optionally substituted by -C(0)R ; and wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, Cχ-C
4
 alkanoylamino, C -C4 alkylsulfonylamino, C -C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, Cχ-C
4
 alkoxycarbonylamino, Cχ-C4 alkoxycarbonyl, cyano, halo, azido, C -C
4
 alkyl, C -C4 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1- 3 halo radicals; and 


 21 each R is independently a C -C
4
 alkyl , C -C
4
22 alkyl-C(0)R , aryl, heteroaryl, aryl-Cχ-C
4
-alkyl or heteroaryl-Cχ-C
4
-alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthiol, amino, C -C
4
 alkanoylamino, Cχ-C
4
 alkylsulfonylamino, Cχ~ C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, C -C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, cyano, halo, azido, Cχ-C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1-3 halo radicals;
22 wherein each R is independently a hydroxy, C -C
4
 alkoxy, aryloxy, aryl-Cχ-C
2
-alkoxy, heteroaryloxy,
23 24 , . heteroaryl-Cχ-C
2
-alkoxy or -NR R radical ; wherein each
23 R is independently a hydrogen, Cχ-C
4
 alkyl, aryl, aryl- Cι-C
2
-alkyl, heteroaryl or heteroaryl-Cχ-C
2
-alkyl
24 radical; and each R is independently a hydrogen or Cχ~
23 24 , , _
C
4
 alkyl radical; or -NR R represents a heterocyclyl or heteroaryl radical; wherein the heterocyclyl, aryl
22 23 23 24 and heteroaryl radicals of R , R and -NR R are optionally substituted by 1-3 radicals of hydroxy, C -C4 alkoxy, C -C
4
 alkylthiol, amino, C -C
4
 alkanoylamino, Cχ~ C
4
 alkylsulfonylamino, Cχ-C
4
 alkylsulfinyl, C -C
4
 alkylsulfonyl, Cχ-C
4
 alkoxycarbonylamino, C -C
4
 alkoxycarbonyl, cyano, halo, azido, C -C
4
 alkyl, Cχ-C4 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1- 3 halo radicals; and
wherein each B is independently a (1) bond;
(2) C -C
8
 alkyl radical optionally substituted by (a) a radical of amino, C -C
4
 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 


alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, hydroxy, Cχ-C
4
 alkoxy, Cχ-C
4
 alkylthio, cyano, and/or (b) 1-3 halo radicals, and/or (c) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthio, cyano, halo, Cχ-C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1-3 halo radicals;
(3) heterocyclyl radical; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, hydroxy, Cχ-C
4
 alkoxy, Cχ-C
4
 alkylthio, cyano, halo, C
1
-C
4
 alkyl, C -C
4
 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1-3 halo radicals;
30 wherein each R is independently
(1) Cχ-C
6
 alkyl radical optionally substituted by 1-3
34 radicals of -CO
2
R , amino, Cχ-C
4
 alkylamino, di- (C
1
-C4 alkyl) amino, Cχ-Cs alkanoylamino, (C -C
4
 alkoxy) carbonylamino, N-((Cχ-C
4
 alkoxy) carbonyl) -N- (Cχ~ C
4
 alkyl) amino, ammocarbonylamino, C -C
4
 alkylsulfonylamino, hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthio, C -C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, cyano, halo, aryl-Cχ-C
4
~alkoxy, aryl-Cχ-C
4
-alkylthio, aryl-Cχ-C
4
-alkylsulfonyl, C
3
-C
8
 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of amino, Cχ~ C
4
 alkylamino, di-(Cχ-C
4
 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C
1
-C
4

alkylsulfonylamino, Cχ-Cs alkanoyl, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthio, C
1
-C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, cyano, halo, C
1
-C
4
 alkyl, Cχ-C
4
 haloalkyl of 1-3 halo radicals or Cχ~ C
4
 haloalkoxy of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C
1
-C
4
 alkylamino, di- (C
1
-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, C -C
4
 alkoxy, Cχ-C
4
 alkylthio, cyano, C -C
4
 alkyl, Cχ-C
4
 haloalkyl of 1-3 halo radicals or Cχ-C
4
 haloalkoxy of 1-3 halo radicals; or
(3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di- (Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, C
1
-C
4
 alkoxy, Cχ-C
4
 alkylthio, cyano, halo, azido, C -C
4
 alkyl, Cχ-C
4
 haloalkyl of 1-3 halo radicals or C -C
4
 haloalkoxy of 1-3 halo radicals;
31 30 each R is independently hydrogen radical or R ;
32 wherein each R is independently hydrogen or Cχ-C
4
 alkyl radical;
33 each R is independently hydrogen or Cχ-C
4
 alkyl radical; and
34 each R is independently hydrogen or C -C
4
 alkyl radical
4. The compound of Claim 3 or a pharmaceutically acceptable salt thereof, wherein 

1 .
R is (1) a Cχ-Cχ
2
 alkyl radical optionally substituted by 1-3 radicals of -OH, -OR , -SR , -S(0)R
3
, 

3 3 4
-C(0)R , -NR R , aryl, heteroaryl, cycloalkyl or heterocyclyl; or (2) an aryl radical optionally substituted by an optionally substituted monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; or (3) a heteroaryl radical optionally substituted by an optionally substituted phenyl or a monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; wherein the phenyl, aryl, heteroaryl, cycloalkyl and heterocyclyl radicals of (1), (2) and (3) are optionally substituted
3 3 3 by 1-3 radicals of hydroxy, -OR , -SR , -S(0)R ,
3 3 3 4 . .
-S(0)
2
R , -C(0)R , -NR R , ammo, acetylamino, methylsulfonylamino, Cχ-C
4
 alkoxycarbonylamino, C -C
4
 alkoxycarbonyl, cyano, halo, C -C
6
 alkyl or -CF3 radicals; provided that the total number of phenyl, aryl, heteroaryl, cycloalkyl and heterocyclyl radicals 

3
 wherein each R is independently an C -C
4
 alkyl, -CF
3
 , aryl, heteroaryl, aryl-Cχ-C
4
~alkyl or heteroaryl-Cχ-C
4
- alkyl radical , wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, acetylamino, methylsulfonylamino, C -C
4
 alkylsulfonyl, C -C
4
 alkoxycarbonylamino, C -C
4
 alkoxycarbonyl, cyano, halo,
4 C
1
-C
4
 alkyl, -CF
3
 or -OCF
3
 ; and each R is independently a hydrogen or methyl radical; 

2 .
R is a hydrogen or methyl radical;
8 11 8 11 12 11 12
V is -CR R - or -CR R -CHR -; wherein R and R are
20 21 22 each independently (1) a hydrogen, -OR , -SR , -C(0)R ,
33 31 33 30 33 32 31 33
-NR -C(0)-R , -NR -C(0)-OR , -NR -C(0)-NR R , -NR - S(0)
2
-R
3
°, -NR
33
-S(0)
2
-NR
32
R
31
, cycloalkyl, aryl or heteroaryl radical; or (2) an C -C
4
 alkyl, C
2
-C
4
 alkenyl or C
2
-C
4
 alkynyl radical optionally substituted with 1-3
20 21 22 33 31 33 radicals of -OR , -SR , -C(0)R , -NR -C(0)-R , -NR -
C(0)-OR°, -NR -C(0)-NR
32
R
31
, -NR
33
-S (0) 
2
~ 
3
 , -NR
33
-S(0)
2
-
32 31
NR R , aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, acetylamino, methylsulfonylamino, methylsulfinyl, methylsulfonyl, Cχ~ C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, cyano, halo, azido, C -C
4
 alkyl, -CF
3
 or -OCF
3
 radicals;
20 . wherein each R is independently a hydrogen, Cχ-C
4
 alkyl, C
2
-C
4
 alkenyl, aryl, heteroaryl, aryl-Cχ-C
4
~ alkyl, heteroaryl-Cχ-C
4
-alkyl , Cχ-C
4
 alkanoyl, aroyl or heteroaroyl radical; wherein the alkyl and alkenyl
2
2
 radicals are optionally substituted by -C(0)R ; and wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, Cχ-C
4
 alkoxy, Cχ-C
4
 alkylthiol, amino, acetylamino, methylsulfonylamino, methylsulfinyl, methylsulfonyl, Cχ~ C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, cyano, halo, azido, C -C
4
 alkyl, -CF
3
 or -OCF
3
 radicals; and 


 21 each R is independently a Cχ-C
4
 alkyl , Cχ-C
4
22 alkyl-C(0)R , aryl, heteroaryl, aryl-Cχ-C
4
-alkyl or heteroaryl-Cχ-C
4
-alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, acetylamino, methylsulfonylamino, methylsulfinyl, methylsulfonyl, C -C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, cyano, halo, azido, Cχ-C alkyl, -CF
3
 or -OCF
3
 radicals;
22 wherein each R is independently a hydroxy, Cχ-C
4
 alkoxy, aryloxy, aryl-Cχ-C
2
-alkoxy, heteroaryloxy,
23 24 heteroaryl-Cι-C
2
-alkoxy or -NR R radical; wherein each
23
R is independently a hydrogen, Cχ-C
4
 alkyl, aryl, aryl- Cχ-C
2
-alkyl, heteroaryl or heteroaryl-Cχ-C
2
-alkyl
24 . radical; and each R is independently a hydrogen or Cχ~
23 24
C
4
 alkyl radical; or -NR R represents a heterocyclyl or heteroaryl radical; wherein the heterocyclyl, aryl
22 23 23 24 and heteroaryl radicals of R , R and -NR R are optionally substituted by 1-3 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, acetylamino, methylsulfonylamino, methylsulfinyl, methylsulfonyl, Cχ~ C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, cyano, halo, azido, C -C
4
 alkyl, -CF
3
 or -OCF
3
 radicals; and
wherein each B is independently a
(1) bond;
(2) Cχ-Cβ alkyl radical optionally substituted by (a) a radical of amino, Cχ-C
4
 alkylamino, di- (Cχ-C
4
 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthio, cyano, and/or (b) 1-3 halo radicals, and/or (c) 1-2 radicals of heterocyclyl, 


aryl or heteroaryl optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di- (Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (C1-C4 alkoxy) carbonylamino, C -C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl, -CF3 or -OCF3 radicals;
(3) heterocyclyl radical; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C -C4 alkylthio, cyano, halo, Cχ-C4 alkyl, -CF
3
 or -OCF3 radicals;
each A is independently a
(1) hydrogen radical;
(2) halo, cyano or nitro radical;
30 31 32 31 32
v
 32 31
(3) -C(0)-R , -C(0)-OR , -C(0)-NR R or -C (NR ) -NR R radical ; (4) -OR
1
, -0-C(0)-R or -0-C(0)-NR R radical;
31 30 30 32 31
(5) -SR , -S(0)-R , -S(0)
2
-R or -S(0)
2
-NR R radical; or
(6) -NR
32
R
31
, -NR
33
-C(0)-R
31
, -NR
33
-C (0) -OR
3
° , -NR -C(O)-
32 31 33 32 32 31 33 30 33
NR R , -NR -C(NR ) -NR R , -NR -S(0)
2
-R or -NR -
32 31 . S(0)
2
-NR R radical;
30 wherein each R is independently (1) Cχ-C
δ
 alkyl radical optionally substituted by 1-3
34 radicals of -CO2R , amino, C -C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N- ( (Cχ-C4 alkoxy) carbonyl) -N- (Cχ~ C4 alkyl) amino, ammocarbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, C1-C4 


alkylthio, C -C
4
 alkylsulfinyl, C -C
4
 alkylsulfonyl, cyano, halo, aryl-Cχ-C
4
-alkoxy, aryl-Cχ-C
4
-alkylthio, aryl-Cχ-C
4
-alkylsulfonyl, C
3
-C
8
 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of amino, Cχ~ C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (C -C
4
 alkoxy) carbonylamino, Cχ-C
4
 alkylsulfonylamino, Cχ-Cs alkanoyl, (C -C
4
 alkoxy) carbonyl, hydroxy, Cχ-C
4
 alkoxy, Cχ-C
4
 alkylthio, C -C
4
 alkylsulfinyl, Cχ-C
4
 alkylsulfonyl, cyano, halo, C -C
4
 alkyl, -CF
3
 or -OCF
3
 radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di-(Cχ-C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, C -C
4
 alkylsulfonylamino, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, C -C
4
 alkoxy, C
1
-C
4
 alkylthio, cyano, Cχ-C
4
 alkyl, C -C
2
 haloalkyl of 1-3 halo radicals or -OCF
3
 ; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C
4
 alkylamino, di- (C -C
4
 alkyl) amino, Cχ-Cs alkanoylamino, (C
1
-C
4
 alkoxy) carbonylamino, C
1
-C
4
 alkylsulfonylamino, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthio, cyano, halo, Cχ-C
4
 alkyl, -CF
3
 or -OCF
3
 radicals;
31 , 30 each R is independently hydrogen radical or R ; and
33 each R is independently a hydrogen or methyl radical
5. The compound of Claim 4 or a pharmaceutically acceptable salt thereof, wherein 


 8 11 , 11 . 20 21
V is -CR R -; wherein R is (1) a hydrogen, -OR , -SR ,
, , 22 33 31 33 30 33
-C(0)R , -NR -C(0)-R , -NR -C(0)-OR , -NR -C(O)-
NR
32
R
31
, -NR
33
-S(0)
2
-R
30
, -NR
33
-S(0)
2
-NR
32
R
31
, cycloalkyl, aryl or heteroaryl radical; or (2) an C -C
4
 alkyl, C
2
-C
4
 alkenyl radical optionally substituted with 1-3 radicals
20 21 22 33 31 33 30 Of -OR , -SR , -C(0)R , -NR -C(0)-R , -NR -C(0)-OR ,
33 32 31 33 , 30 33 32 31
-NR -C(0)-NR R , -NR -S(0)
2
-R , -NR -S(0)
2
-NR R , aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-2 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, acetylamino, methylsulfonylamino, methylsulfinyl, methylsulfonyl, Cχ~ C
4
 alkoxycarbonylamino, C -C
4
 alkoxycarbonyl, cyano, halo, azido, Cχ-C
4
 alkyl, -CF
3
 or -OCF
3
 radicals.
6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof, wherein
1 R is (1) an Cχ-Cχ
2
 alkyl radical optionally substituted by 1-3 radicals of -OH, -OR
3
, -SR
3
, 


 -NRV, aryl, heteroaryl, cycloalkyl or heterocyclyl; or (2) an aryl radical optionally substituted by an optionally substituted monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; or (3) a heteroaryl radical optionally substituted by an optionally substituted phenyl or a monocyclic heteroaryl or heterocyclyl radical of 5-6 ring members which is optionally substituted by a phenyl radical or monocyclic heteroaryl radical of 5-6 ring members; wherein the phenyl, aryl, heteroaryl, cycloalkyl and heterocyclyl radicals of (1) , (2) and (3) are optionally substituted by 1-3 radicals 

r
- ■, 
3
 3 3 3 4 . of hydroxy, -OR , -SR , -S(0)
2
R , -NR R , ammo, acetylamino, methylsulfonylamino, Cχ-C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, cyano, halo, Cχ-C
δ
 alkyl or -CF
3
 radicals; provided that the total number of phenyl, aryl, heteroaryl, cycloalkyl and
1 heterocyclyl radicals in R is 0-2;
3 wherein each R is independently a Cχ-C
4
 alkyl, -CF
3
, aryl, heteroaryl, aryl-Cχ-C
2
-alkyl or heteroaryl-Cχ-C
2
- alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, amino, acetylamino, methylsulfonylamino, C -C
4
 alkylsulfonyl, C -C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, cyano, halo, Cχ-C alkyl, -CF
3
 or -OCF
3;
2 R is a hydrogen radical;
8 11 . 11 20 21
V is -CR R -; wherein R is (1) a hydrogen, -OR , -SR ,
22 33 31 33 30 33 -C(0)R , -NR -C(0)-R , -NR -C(0)-OR , -NR -C(O)-
32 31 33 30 33 32 31 , , ,
NR R , -NR -S(0)
2
-R , -NR -S(0)
2
-NR R , cycloalkyl, aryl or heteroaryl radical; or (2) an Cχ-C
4
 alkyl or C -
C
4
 alkenyl radical optionally substituted with 1-3
20 21 22 33 31 33 radicals of -OR , -SR , -C ( 0 ) R , -NR -C (0 ) -R , -NR -
30 33 32 31 33 30 33 , 
%
 C(0)-OR , -NR -C(0)-NR R , -NR -S(0)
2
-R , -NR -S(0)
2
-
32 31
NR R , aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-2 radicals of hydroxy, Cχ-C
4
 alkoxy, C
1
-C
4
 alkylthiol, methylsulfonyl, halo, azido, C -C
4
 alkyl, -CF
3
 or -OCF
3
 radicals; 


 22 wherein each R is independently a hydroxy, C
1
-C
4
 alkoxy, aryloxy, aryl-Cχ-C
2
-alkoxy, heteroaryloxy,
23 24 heteroaryl-Cχ-C
2
-alkoxy or -NR R radical; wherein each
23 .
R is independently a hydrogen, Cχ-C
4
 alkyl, aryl, aryl- Cχ-C
2
-alkyl, heteroaryl or heteroaryl-Cχ-C
2
-alkyl
24 radical; and each R is independently a hydrogen or Cχ~
23 24
C
4
 alkyl radical; or -NR R represents a heterocyclyl or heteroaryl radical; wherein the heterocyclyl, aryl
22 23 23 24 and heteroaryl radicals of R , R and -NR R are optionally substituted by 1-2 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, halo, azido, Cχ-C
4
 alkyl, -CF
3
 or -OCF
3
 radicals; and
wherein each B is independently a (1) bond;
(2) C -C
4
 alkyl radical optionally substituted by (a) a radical of amino, C -C
2
 alkylamino, di-(Cχ-C
2
 alkyDamino, Cχ-C
2
 alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, hydroxy, C -C
2
 alkoxy, and/or (b) 1-2 halo radicals, and/or (c) a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-2 radicals of amino, C -C
2
 alkylamino, di- (Cχ-C2 alkyDamino, C -C
2
 alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
2
 alkylsulfonylamino, hydroxy, Cχ-C alkoxy, Cχ-C
2
 alkylthio, halo, C -C
4
 alkyl, -CF
3
 or
-OCF
3
 radicals;
(3) heterocyclyl radical; or
(4) aryl or heteroaryl radical optionally substituted by 1-2 radicals of amino, C -C2 alkylamino, di-(Cχ-C2 alkyl) amino, C -C
2
 alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
2
 alkylsulfonylamino, hydroxy, C -C
2
 alkoxy, C -C
2
 alkylthio, halo, Cχ-C
4
 alkyl, -CF3 or -OCF
3
 radicals; 


each A is independently a
(1) hydrogen radical;
(2) halo radical;
30 31 32 31 32 32 31 (3) -C(0)-R , -C(0)-OR , -C(0)-NR R or -C (NR ) -NR R radical;
31
(4) -OR radical;
(5) -SR \ -S(0)
2
-R or -S(0)
2
-NR
32
R 
X
 radical; or
(6) -NR
32
R
31
, -NR
33
-C(0)-R
31
, -NR
33
-C (0) -OR
3
°, -NR
33
-C(0)- NR
32
R
31
, -NR
33
-S(0)
2
-R
3
° or -NR 
3
-S (0) 
2
-NR
32
R
31
 radical;
30 . wherein each R is independently
(1) -CF
3
 or Cχ-C
4
 alkyl radical optionally substituted
34 by 1-2 radicals of -CO
2
R , amino, C -C
2
 alkylamino, di- (Cχ-C
2
 alkyl) amino, Cχ-C
2
 alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, N- ( (Cχ-C
4
 alkoxy) carbonyl) -N- (Cχ~ C
4
 alkyDamino, hydroxy, Cχ-C
4
 alkoxy, or aryl-Cχ-C - alkoxy, heterocyclyl, aryl or heteroaryl radicals, wherein the heterocyclyl, aryl and heteroaryl radicals are optionally substituted by 1-3 radicals of amino, Cχ~ C alkylamino, di- (Cχ-C
2
 alkyDamino, Cχ-C
2
 alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-Cs alkanoyl, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, Cχ-C
4
 alkoxy, halo, C -C
4
 alkyl, -CF
3
 or -OCF
3
 radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C
4
 alkoxy) carbonyl, hydroxy or Cχ-C
4
 alkyl ; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, Cχ-C
2
 alkylamino, di-(Cχ-C
2
 alkyDamino, Cχ-C
2
 alkanoylamino, hydroxy, C -C2 alkoxy, halo, C -C
4
 alkyl, -CF
3
 or -OCF
3
 radicals;
31 30 each R is independently hydrogen radical or R ; and 


wherein cycloalkyl is a monocyclic carbocyclic alkyl radical of 3-6 ring members, which is optionally partially unsaturated or benzo-fused; and heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals.
7. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
i . R is (1) an C -C
4
 alkyl radical substituted by 1-2
3 3 4 radicals of -OH, -OR , -NR R , aryl or heteroaryl; or (2) an aryl radical optionally substituted by a monocyclic heteroaryl radical of 5-6 ring members; or (3) a heteroaryl radical optionally substituted by a phenyl radical ; wherein the phenyl , aryl and heteroaryl radicals of (1) , (2) and (3) are optionally substituted
3 3 3 3 4 by 1-2 radicals of hydroxy, -OR , -SR , -S(0)
2
R , -NR R , amino, acetylamino, methylsulfonylamino, C -C
4
 alkoxycarbonylamino, C
1
-C
4
 alkoxycarbonyl, halo, C -C
6
 alkyl or -CF
3
 radicals; provided that the total number
1 . of phenyl, aryl and heteroaryl radicals in R is 0-2;
3 wherein each R is independently a C -C
4
 alkyl, -CF
3
, aryl, heteroaryl, aryl-Cχ-C
2
-alkyl or heteroaryl-Cχ-C - alkyl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, Cχ-C
2
 alkoxy, C -C
2
 alkylthiol, amino, acetylamino, methylsulfonylamino, Cχ-C
2
 alkylsulfonyl, C -C
4

alkoxycarbonylamino , C -C
4
 alkoxycarbonyl , halo , Cχ-C
2
 alkyl , -CF
3
 or -OCF
3
 ;
8 11 11 20 33
V is -CR R -; wherein R is (1) a hydrogen, -OR , -NR -
31 33 30 C(0)-R , -NR -S(0)
2
-R , cycloalkyl, aryl or heteroaryl radical; or (2) an Cχ-C
4
 alkyl or C
2
-C
4
 alkenyl radical
20 21 optionally substituted with 1-2 radicals of -OR , -SR ,
-C(0)R
22
, -NR
33
-C(0)-R
31
, -NR
33
-S(0)
2
-R
3
°, aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1- 2 radicals of hydroxy, C -C
2
 alkoxy, C -C
2
 alkylthiol, halo, azido, Cχ-C
2
 alkyl, -CF
3
 or -OCF
3
 radicals;
20 wherein each R is independently a hydrogen, C -C
4
22 alkyl, C -C
4
 alkyl-C(0)R , C -C
4
 alkenyl, aryl, heteroaryl, aryl-Cχ-C
2
-alkyl , heteroaryl-Cχ-C
2
-alkyl or C -C
4
 alkanoyl radical; and wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C -C
4
 alkoxy, C
1
-C
4
 alkylthiol, halo, azido, Cχ-C
2
 alkyl, -CF
3
 or -OCF
3
 radicals; and
21 each R is independently a Cχ-C
4
 alkyl, Cχ-C
4
22 alkyl-C(0)R , aryl, heteroaryl, aryl-Cχ-C
2
-alkyl or heteroaryl-Cχ-C
2
-alkyl radical; wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of hydroxy, C -C
4
 alkoxy, C -C
4
 alkylthiol, halo, azido, Cχ-C
2
 alkyl, -CF
3
 or -OCF
3
 radicals;
22 23 24 wherein each R is independently a hydroxy or -NR R
23 radical; wherein each R is independently a hydrogen, Cχ-C
2
 alkyl, aryl, aryl-Cχ-C
2
-alkyl, heteroaryl or
24 . heteroaryl-Cχ-C
2
-alkyl radical; and each R is 


independently a hydrogen or C -C
2
 alkyl radical; or
23 24
-NR R represents a heteroaryl radical; wherein the
22 23 23 24 aryl and heteroaryl radicals of R , R and -NR R are optionally substituted by 1-2 radicals of hydroxy, C -C
2
 alkoxy, Cχ-C
2
 alkylthiol, halo, azido, Cχ-C
2
 alkyl, -CF
3
 or -OCF
3
 radicals; and
wherein each B is independently a
(1) bond; (2) C
1
-C
4
 alkyl radical; or
(3) aryl or heteroaryl radical optionally substituted by a radical of amino, Cχ-C
2
 alkylamino, di-(Cχ-C
2
 alkyl) amino, Cχ-C
2
 alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-C
2
 alkylsulfonylamino, hydroxy, C -C
2
 alkoxy, Cχ-C
2
 alkylthio, halo, C -C
4
 alkyl, -CF3 or
-OCF
3
 radicals;
each A is independently a (1) hydrogen radical; (2) halo radical;
30 32 31 32 32 31 -. -
(3) -C(0)-R , -C(0)-NR R or -C (NR ) -NR R radical;
31
(4) -OR radical;
(5) -SR , -S(0)
2
-R or -S(0)
2
-NR R radical; or
32 31 33 , 31 33 , 
%
 30 , . ,
(6) -NR R , -NR -C(0)-R or -NR -S(0)
2
-R radical;
30 wherein each R is independently
(1) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C
4
 alkoxy) carbonyl, hydroxy or C -C
4
 alkyl ; or (2) heteroaryl radicals optionally substituted by 1-2 radicals of amino, Cχ-C
2
 alkylamino, di-(Cχ-C
2
 alkyDamino, Cχ-C
2
 alkanoylamino, hydroxy, Cχ-C
2
 alkoxy, halo, Cχ-C
4
 alkyl, -CF
3
 or -OCF
3
 radicals; and 


 31 each R is independently hydrogen radical or
(1) -CF
3
 or C
X
-C
4
 alkyl radical optionally substituted by 1-2 radicals of hydroxy, Cχ-C
2
 alkoxy or aryl-Cχ-C
2
- alkoxy, aryl or heteroaryl radicals, wherein the aryl and heteroaryl radicals are optionally substituted by 1- 2 radicals of amino, Cχ-C alkylamino, di-(Cχ-C
2
 alkyl) amino, Cχ-C alkanoylamino, (Cχ-C
4
 alkoxy) carbonylamino, Cχ-Cs alkanoyl, (Cχ-C
4
 alkoxy) carbonyl, hydroxy, C -C
4
 alkoxy, halo, Cχ-C
4
 alkyl, -CF
3
 or -OCF
3
 radicals; or
(2) aryl or heteroaryl radical optionally substituted by 1-2 radicals of amino, Cχ-C
2
 alkylamino, di-(Cχ-C alkyDamino, Cχ-C alkanoylamino, hydroxy, Cχ-C
2
 alkoxy, halo, Cχ-C
4
 alkyl, -CF
3
 or -OCF
3
 radicals.
8. The compound of Claim 7 or a pharmaceutically acceptable salt thereof, wherein
1 R is aryl or heteroaryl radicals optionally substituted
3 3 3 3 4 by 1-2 radicals of hydroxy, -OR , -SR , -S(0) R , -NR R , amino, acetylamino, methylsulfonylamino, Cχ-C
4
 alkoxycarbonylamino, Cχ-C
4
 alkoxycarbonyl, halo, C -C
6
 alkyl or -CF
3
 radicals; provided that the total number
1 of aryl and heteroaryl radicals in R is 1-2;
3 wherein each R is independently a Cχ-C
4
 alkyl, -CF
3
 , aryl, heteroaryl, arylmethyl or heteroarylmethyl radical;
8 11 11 20 33
V is -CR R -; wherein R is (1) a hydrogen, -OR , -NR -
31 33 30
C(0)-R , -NR -S(0)
2
-R , cycloalkyl, aryl or heteroaryl 


radical; or (2) an C
1
-C
4
 alkyl or C
2
-C
4
 alkenyl radical
20 33 optionally substituted with 1-2 radicals of -OR , -NR -
31 33 30
C(0)-R , -NR -S(0) -R , aryl or heteroaryl; wherein the cycloalkyl, aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-2 radicals of hydroxy, Cχ-C
2
 alkoxy, Cχ-C
2
 alkylthiol, halo, azido, Cχ-C
2
 alkyl, -CF
3
 or -OCF
3
 radicals;
20 wherein each R is independently a hydrogen, C -C
4
 alkyl, C
2
-C
4
 alkenyl, aryl, heteroaryl, aryl-Cχ-C
2
- alkyl, heteroaryl-Cχ-C
2
-alkyl or Cχ-C
4
 alkanoyl radical; and
wherein each B is independently a (1) bond;
(2) Cχ-C
4
 alkyl radical; or
(3) aryl or heteroaryl radical;
each A is independently a (1) hydrogen radical;
(2) halo radical; or
(3) -C(0)-R
3
° or -C(0)-NR
32
R
31
 radical;
wherein each R is independently a heterocyclyl radical optionally substituted by Cχ-C
4
 alkyl;
31 each R is independently hydrogen radical or (1) -CF
3
 or Cχ-C
4
 alkyl radical optionally substituted by 1-2 radicals of aryl or heteroaryl radicals; or (2) aryl or heteroaryl radical; and
32 wherein each R is independently a hydrogen or methyl radical. 

9. The compound of Claim 8 or a pharmaceutically acceptable salt thereof, wherein
i . R is an aryl radical optionally substituted by 1-2
3 3 3 4 radicals of hydroxy, -OR , -S(0)
2
R , -NR R , amino, acetylamino, methylsulfonylamino, halo, Cχ-C
4
 alkyl or -CF
3
 radicals; provided that the total number of aryl and heteroaryl radicals in R is 1-2;
8 11 . 11 20
V is -CR R -; wherein R is (1) a hydrogen, -OR , aryl or heteroaryl radical; or (2) an Cχ-C
4
 alkyl or C
2
-C
4
 alkenyl radical optionally substituted with 1-2 radicals
20 of -OR , aryl or heteroaryl; wherein the aryl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-2 radicals of hydroxy, C -C
2
 alkoxy, halo, C
1
-C
2
 alkyl, -CF
3
 or -OCF
3
 radicals; provided the
11 total number of aryl and heteroaryl radicals m R is
0-2;
5 6 7 8 9 10
R , R , R , R , R and R are each a hydrogen radical; or
5 6 6 7 7 8 , one of CR -CR , CR -CR or CR -CR is C=C; and
wherein heterocyclyl is a radical of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholmyl, 4-benzyl-piperazin-l-yl, pyrimidinyl, tetrahydrofuryl , pyrazolidonyl, pyrazolinyl, pyridazinonyl, pyrrolidonyl, tetrahydrothienyl or its sulfoxide or sulfone derivative, 2 , 3-dihydroindolyl , tetrahydroquinolinyl , 1, 2, 3, 4-tetrahydroisoquinolinyl, 1, 2 , 3 , 4-tetrahydro-l- oxo-isoquinolinyl, 2 , 3-dihydrobenzofuryl, benzopy anyl , methylenedioxyphenyl or ethylenedioxyphenyl; aryl is a phenyl, biphenyl or naphthyl radical; and heteroaryl is a radical of imidazolyl, pyrrolyl, pyrazolyl, pyridyl, 


pyrazinyl, triazolyl, furyl, thienyl, oxazolyl, thiazolyl, indolyl, quinolinyl, isoquinolinyl, 5,6,7,8- tetrahydroquinolyl, 5,6,7, 8-tetrahydroisoquinolinyl, quinoxalinyl, benzothiazolyl, S-carbolinyl, benzofuryl, benzimidazolyl or benzoxazolyl .
10. The compound of Claim 9 or a pharmaceutically acceptable salt thereof, wherein
R is an phenyl radical optionally substituted by 1-2
3 3 3 4 radicals of hydroxy, -OR , -S(0)
2
R , -NR R , ammo, acetylamino, methylsulfonylamino, halo, Cχ-C
4
 alkyl or -CF
3
 radicals; provided that the total number of aryl and heteroaryl radicals m R is 1-2;
wherein each R is independently an C -C
4
 alkyl, -CF
3
, phenyl, heteroaryl, phenylmethyl or heteroarylmethyl radical;
8 11 11 . 20
V is -CR R -; wherein R is (1) a hydrogen, -OR , phenyl or heteroaryl radical; or (2) an C -C
4
 alkyl or
C
2
-C
4
 alkenyl radical optionally substituted with 1-2
20 radicals of -OR , phenyl or heteroaryl; wherein the phenyl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-2 radicals of hydroxy, Cχ-C
2
 alkoxy, halo, Cχ-C
2
 alkyl, -CF
3
 or -OCF
3
 radicals; provided the total number of aryl and heteroaryl
11 . radicals m R is 0-2;
20 wherein each R is independently a hydrogen, Cχ-C
4
 alkyl, C
2
-C
4
 alkenyl, phenyl, heteroaryl, phenyl-Cχ-C
2
- alkyl, heteroaryl-Cχ-C
2
-alkyl or radical; and 


wherein heterocyclyl is a radical of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholmyl, 4-benzyl-piperazin-l-yl or pyrimidinyl; and heteroaryl is a radical of imidazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl , benzothiazolyl, benzofuryl, benzimidazolyl or benzoxazolyl .
11. The compound of Claim 10 or a pharmaceutically acceptable salt thereof, wherein
1
R is an phenyl radical optionally substituted by 1-2 radicals of hydroxy, -OR , halo, methyl or -CF
3
 radicals; provided that the total number of aryl and heteroaryl radicals in R is 1-2;
3 wherein each R is independently an methyl, -CF
3
 , phenyl, heteroaryl, phenylmethyl or heteroarylmethyl radical;
8 11 11 20
V is -CR R -; wherein R is (1) a hydrogen, -OR , phenyl or heteroaryl radical; or (2) an Cχ-C
4
 alkyl or C
2
-C
4
 alkenyl radical optionally substituted with 1-2
20 radicals of -OR , phenyl or heteroaryl; wherein the phenyl and heteroaryl radicals of (1) and (2) are optionally substituted by 1-2 radicals of hydroxy, methoxy, halo, methyl, -CF
3
 or -OCF
3
 radicals; provided the total number of aryl and heteroaryl radicals in R is 0-2; and 


 20 wherein each R is independently a hydrogen, methyl, propenyl, phenyl, heteroaryl, phenyl-Cχ-C
2
-alkyl or heteroaryl-Cχ-C
2
-alkyl radical.
12. The compound of Claim 1 or a pharmaceutically acceptable salt thereof, which is
cis-3 -benzyl-1- (4-methoxyphenylsulfonyl) -azepane-2- hydroxamic acid; trans-3 -benzyl-1- (4-methoxyphenylsulfonyl) -azepane-2- hydroxamic acid; trans-3 -phenyl-1- (4-methoxyphenylsulfonyl) -azepane-2- hydroxamic acid;
1- (4-methoxyphenylsulfonyl) -azepane-2-hydroxamic acid; acetic acid (2-hydroxycarbamoyl-l- (4- methoxyphenylsulfonyl) -azepan-3-yl)methyl ester;
3-hydroxymethyl-l- (4-methoxyphenylsulfonyl) -azepane-2- hydroxamic acid;
3-benzyloxymethyl-l- (4-methoxyphenylsulfonyl) -azepane-2- hydroxamic acid;
1- (4-methoxyphenylsulfonyl) -3-phenylsulfanylmethy1- azepane-2-hydroxamic acid;
1- (4-methoxyphenylsulfonyl) -3-styryl-azepane-2- hydroxamic acid; 3- (2-hydroxycarbamoyl-l- (4-methoxyphenylsulfonyl) - azepan-3-yl) acrylic acid; acetic acid (2-hydroxycarbamoyl-l- (4- methoxyphenylsulfonyl) -2,3,4, 7-tetrahydro-lH-azepin-3- yl) methyl ester;
3-hydroxymethyl-l- (4-methoxyphenylsulfonyl) -2,3,4,7- tetrahydro-lH-azepine-2-hydroxamic acid; 3-benzyloxymethyl-l- (4-methoxyphenylsulfonyl) -2,3,4,7- tetrahydro-lH-azepine-2-hydroxamic acid;
1- (4-methoxyphenylsulfonyl) -3-phenylsulfanylmethyl- 2,3,4, 7-tetrahydro-lH-azepine-2-hydroxamic acid; 


3-benzofuran-2-yl-l- (4-methoxyphenylsulfonyl) -2,3,4,7- tetrahydro-lH-azepine-2-hydroxamic acid;
1- (4-methoxyphenylsulfonyl) -azepane-2 , 3-dicarboxylic acid 2- (hydroxamide) 3- (phenmethylamide) ;
1- (4-methoxyphenylsulfonyl) -azepane-2 , 3-dicarboxylic acid 2- (hydroxamide) 3- (phenethylamide) ; 1- (4-methoxyphenylsulfonyl) -azepane-2 , 3-dicarboxylic acid 2- (hydroxamide) 3- (phenpropylamide) ;
1- (4-methoxyphenylsulfonyl) -azepane-2, 3-dicarboxylic acid 2- (hydroxamide) 3- (4-phenoxy-2-ethylamide) ;
1- (4-methoxyphenylsulfonyl) -azepane-2, 3-dicarboxylic acid 2- (hydroxamide) 3- (phenylmethylsulfanylethylamide)
1- (4-methoxyphenylsulfonyl) -azepane-2, 3-dicarboxylic acid 2- (hydroxamide) 3- (4-Phenoxyphenethylamide) ;
Cis-3- (4-Phenylbenzyl) -1- (4-methoxyphenylsulfonyl) - azepane-2-hydroxamic acid; Trans-3- (4-Phenylbenzyl) -1- (4-methoxyphenylsulfonyl) 
■
 azepane-2-hydroxamic acid;
Trans-3 -Methyl-1- (4-methoxyphenylsulfonyl) -azepane-2- hydroxamic acid; or
(2-Hydroxycarbamoyl-1- (4-methoxyphenylsulfonyl) -2,3,4,7- tetrahydro-lH-azepine-3-yl) -carbamic acid benzyl ester.
13. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
14. A method for prophylaxis or treatment of inflammation comprising administering an effective amount of a compound of Claim 1.
15. A method for prophylaxis or treatment of inflammation comprising administering an effective amount of a composition of Claim 13. 

16. A method for prophylaxis or treatment of connective tissue degradation comprising administering an effective amount of a compound of Claim 1.
17. A method for prophylaxis or treatment of connective tissue degradation comprising administering an effective amount of a composition of Claim 13.
18. A method of treating rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; HIV infections; cytomegalovirus (CMV) infections; influenza; adenovirus infections; the herpesvirus infections; herpes zoster; muscle degeneration; cachexia; Reiter's syndrome; type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; or fever or mylagias due to infection comprising administering an effective amount of a compound of Claim 1.
19. A method of treating rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; HIV infections; cytomegalovirus (CMV) infections; influenza; adenovirus infections; the herpesvirus infections; herpes zoster; muscle degeneration; cachexia; Reiter's syndrome; type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; multiple sclerosis; 


cerebral malaria; sepsis; septic shock; toxic shock syndrome; or fever or mylagias due to infection comprising administering an effective amount of a composition of Claim 13.
20. A method of lowering plasma concentrations of TNF-α comprising administering an effective amount of a compound of Claim 1.
21. A method of lowering plasma concentrations of TNF-α comprising administering an effective amount of a composition of Claim 13.
22. A method of treating neuroinflammatory disorders or angiogenesis dependent diseases comprising administering an effective amount of a compound of Claim
1.
23. A method of treating neuroinflammatory disorders or angiogenesis dependent diseases comprising administering an effective amount of a composition of Claim 13.
24. A method of treating rheumatoid arthritis, osteoarthritis, osteopenias, periodontitis, gingivitis, corneal ulceration, epidermal ulceration, gastric ulceration, tumour metastasis, tumour invasion, tumour growth, myelin degradation, cancer, psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas, hemangiomas, nephritis, pulmonary inflammation or restenosis comprising administering an effective amount of a compound of Claim 1.
25. A method of treating rheumatoid arthritis, osteoarthritis, osteopenias, periodontitis, gingivitis, corneal ulceration, epidermal ulceration, gastric 


ulceration, tumour metastasis, tumour invasion, tumour growth, myelin degradation, cancer, psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas, hemangiomas, nephritis, pulmonary inflammation or restenosis comprising administering an effective amount of a composition of Claim 13.
26. Use of a compound of Claims 1 to 12 for the preparation of a composition for use in the prophylaxis or treatment of inflammation.
27. Use of a compound of Claims 1 to 12 for the preparation of a composition for use in the prophylaxis or treatment of connective tissue degradation.
28. Use of a compound of Claims 1 to 12 for the preparation of a composition for use in treating rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS) ; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; HIV infections; cytomegalovirus (CMV) infections; influenza; adenovirus infections; the herpesvirus infections; herpes zoster; muscle degeneration; cachexia; Reiter's syndrome; type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; or fever or mylagias due to infection.
29. Use of a compound of Claims 1 to 12 for the preparation of a composition for use in lowering plasma concentrations of TNF-α. 

30. Use of a compound of Claims 1 to 12 for the preparation of a composition for use in treating neuromflammatory disorders or angiogenesis dependent diseases .
31. Use of a compound of Claims 1 to 12 for the preparation of a composition for use in treating rheumatoid arthritis, osteoarthritis, osteopenias, periodontitis, gingivitis, corneal ulceration, epidermal ulceration, gastric ulceration, tumour metastasis, tumour invasion, tumour growth, myelin degradation, cancer, psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas, hemangiomas, nephritis, pulmonary inflammation or restenosis. 

</CLAIMS>
</TEXT>
</DOC>
